MedWatch

Nykode initiates clinical study of "pan-variant" Covid-19 vaccine

Nykode Therapeutics has initiated a clinical trial of its Covid-19 vaccine candidate, which is designed to fight emerging variants like Omicron by targeting T cells. "It's our objective to create a real pan-variant vaccine," says CEO Michael Engsig.

Michael Engsig, CEO of Nykode Therapeutics | Photo: Nykode Therapeutics / PR

Norwegian biotech firm Nykode Therapeutics, formerly known as Vaccibody, has dosed the first patient in a phase I/II trial involving its T-cell focused vaccine candidate, dubbed VB-D-01, designed to address new Covid-19 variants including Omicron, which are cause for concern the world over.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs